Synergistic Neutralization of Simian-Human Immunodeficiency Virus SHIV-vpu+ by Triple and Quadruple Combinations of Human Monoclonal Antibodies and High-Titer Anti-Human Immunodeficiency Virus Type 1 Immunoglobulins

ABSTRACT We have tested triple and quadruple combinations of human monoclonal antibodies (MAbs), which are directed against various epitopes on human immunodeficiency virus type 1 (HIV-1) envelope glycoproteins, and a high-titer anti-HIV-1 human immunoglobulin (HIVIG) preparation for their abilities to neutralize a chimeric simian-human immunodeficiency virus (SHIV-vpu+). This virus encodes the HIV-1 strain IIIB env, tat, rev, and vpu genes. The quantitative nature of the Chou-Talalay method (Adv. Enzyme Regul. 22:27–55, 1984) allows ranking of various combinations under identical experimental conditions. Of all triple combinations tested, the most potent neutralization was seen with MAbs 694/98D plus 2F5 plus 2G12 (directed against domains on V3, gp41, and gp120, respectively) as measured by the total MAb concentration required to reach 90% neutralization (90% effective concentration [EC90], 2.0 μg/ml). All triple combinations involving MAbs and/or HIVIG that were tested yielded synergy with combination index values of <1; the dose reduction indices (DRIs) ranged from 3.1 to 26.2 at 90% neutralization. When four MAbs (the previous three plus MAb F105, directed against the CD4 binding site) were combined, higher neutralization potency (EC90, 1.8 μg/ml) and a higher degree of synergy compared to any triple combination were seen. The mean DRIs of the quadruple combination were approximately twice that of the most synergistic triple combination. We conclude that human MAbs targeting different HIV-1 envelope glycoprotein epitopes exhibit strong synergy when used in combination, a fact that could be exploited clinically for passive immunoprophylaxis against HIV-1.

[1]  J. Sodroski,et al.  Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region , 1992, Journal of virology.

[2]  R. Kurth,et al.  Neither whole inactivated virus immunogen nor passive immunoglobulin transfer protects against SIVagm infection in the African green monkey natural host. , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[3]  T. Chou,et al.  Synergism and antagonism in chemotherapy , 1991 .

[4]  M. Hilgartner,et al.  A human monoclonal antibody against the CD4-binding site of HIV1 gp120 exhibits potent, broadly neutralizing activity. , 1991, Research in virology.

[5]  S. Zolla-Pazner,et al.  Complement activation by human monoclonal antibodies to human immunodeficiency virus , 1993, Journal of virology.

[6]  J. Sodroski,et al.  A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys , 1996, Journal of virology.

[7]  S. Zolla-Pazner,et al.  Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody , 1992, Journal of virology.

[8]  J. Sodroski,et al.  An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys , 1996, Journal of virology.

[9]  D. Kufe,et al.  A broadly neutralizing monoclonal antibody that recognizes the V3 region of human immunodeficiency virus type 1 glycoprotein gp120. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[10]  D R Burton,et al.  Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins. , 1997, AIDS research and human retroviruses.

[11]  L. Arthur,et al.  Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[12]  S. Zolla-Pazner,et al.  Human monoclonal antibodies to the V3 loop of HIV-1 gp120 mediate variable and distinct effects on binding and viral neutralization by a human monoclonal antibody to the CD4 binding site. , 1993, Journal of acquired immune deficiency syndromes.

[13]  H. McClure,et al.  Chimeric simian/human immunodeficiency virus that causes progressive loss of CD4+ T cells and AIDS in pig-tailed macaques , 1996, Journal of virology.

[14]  A. Rosenthal,et al.  Passive immunization of rhesus macaques against SIV infection and disease. , 1995, AIDS research and human retroviruses.

[15]  S. Zolla-Pazner,et al.  Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies. , 1997, International immunology.

[16]  M. Gardner,et al.  Passive immunization of macaques against SIV infection , 1994, Journal of medical primatology.

[17]  S. Zolla-Pazner,et al.  Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. , 1993, Journal of immunology.

[18]  D. Montefiori,et al.  Passively transferred antibodies directed against conserved regions of SIV envelope protect macaques from SIV infection. , 1993, Vaccine.

[19]  A. Pinter,et al.  Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site , 1996, Journal of virology.

[20]  A. Profy,et al.  Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1 , 1990, Science.

[21]  D R Burton,et al.  Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. , 1994, Science.

[22]  L. Cavacini,et al.  Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120. , 1993, Journal of acquired immune deficiency syndromes.

[23]  K. Mills,et al.  Passive immunization of cynomolgus macaques with immune sera or a pool of neutralizing monoclonal antibodies failed to protect against challenge with SIVmac251. , 1994, AIDS research and human retroviruses.

[24]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[25]  R. Gallo,et al.  Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[26]  S. Zolla-Pazner,et al.  Production of human monoclonal antibodies specific for conformational and linear non-V3 epitopes of gp120. , 1992, AIDS research and human retroviruses.

[27]  L. Cavacini,et al.  Loss of serum antibodies to a conformational epitope of HIV-1/gp120 identified by a human monoclonal antibody is associated with disease progression. , 1993, Journal of acquired immune deficiency syndromes.

[28]  D. Baltimore,et al.  Isolation and properties of Moloney murine leukemia virus mutants: use of a rapid assay for release of virion reverse transcriptase , 1981, Journal of virology.

[29]  J. Sodroski,et al.  Utility of SHIV for testing HIV-1 vaccine candidates in macaques. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[30]  A. Trkola,et al.  Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 , 1996, Journal of virology.

[31]  E. Emini,et al.  Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Sodroski,et al.  Cooperativity of neutralizing antibodies directed against the V3 and CD4 binding regions of the human immunodeficiency virus gp120 envelope glycoprotein. , 1992, Journal of acquired immune deficiency syndromes.

[33]  T. Hideshima,et al.  An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection. , 1991, Journal of immunology.

[34]  T. Chou,et al.  Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120. , 1992, AIDS research and human retroviruses.

[35]  D. Montefiori,et al.  Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay , 1988, Journal of clinical microbiology.

[36]  A. Trkola,et al.  Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS , 1994, Journal of virology.

[37]  M. Kieny,et al.  High viral load and CD4 lymphopenia in rhesus and cynomolgus macaques infected by a chimeric primate lentivirus constructed using the env, rev, tat, and vpu genes from HIV-1 Lai. , 1996, Virology.

[38]  S. Zolla-Pazner,et al.  Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies , 1994, Journal of virology.

[39]  A. Trkola,et al.  Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG , 1995, Journal of virology.

[40]  M. Reitz,et al.  Sequence of simian immunodeficiency virus and its relationship to the human immunodeficiency viruses , 1987, Nature.

[41]  J. Albert,et al.  Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys , 1991, Nature.

[42]  D. Dimitrov,et al.  Synergistic inhibition of human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion and infection by an antibody to CD4 domain 2 in combination with anti-gp120 antibodies , 1995, Journal of virology.

[43]  W. Schleif,et al.  Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody , 1992, Nature.

[44]  J. Sodroski,et al.  Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein , 1996, Journal of virology.

[45]  S. Zolla-Pazner,et al.  Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent strains. , 1992, AIDS research and human retroviruses.

[46]  D. Ho,et al.  Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody , 1991, Journal of virology.

[47]  H. Katinger,et al.  The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate , 1996, Journal of virology.

[48]  T. Chou,et al.  Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. , 2005, European journal of biochemistry.